Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

Summary

This phase II trial studies how well nivolumab and ipilimumab work in treating patients with kidney cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2017-12-13

Primary completion

2025-11-21

Completion

2025-11-21

Outcome

Outcome not reported

Stopped (Enrollment): “The study met its prespecified futility criteria during the prespecified interim futility analysis after enrolling the first cohort of 10 patients.”

Drugs

Indications